Our vision: recovery and prediction
Dextrain started from an observation: there is a lack of reliable and precise tools to measure dexterity and its different components, both in research and in the clinic but also to rehabilitate it and train it intensively. From this observation, Påvel Lindberg and Maxime Térémetz, researchers at Inserm, in collaboration with Mathieu Boucher, CEO of Sensix, developed the Dextrain method to precisely quantify dexterity and its key components and train and rehabilitate dexterity by focusing precisely and intensely on these components.
This work has resulted in numerous scientific publications showing the scientific and clinical interest of the Dextrain approach.
In 2021, in order to continue these advances, the inventors are joining forces with ARCHOS, the French leader in portable technology, and Erganeo, an investment company specializing in technologies resulting from research, to create the Dextrain company.
Our solutions provide early detection of neurological hand impairments and intense targeted training through personalized exercises.
Dextrain is the only solution providing a multicomponent dexterity assessment with a method based on neuroscience.
Dextrain possesses the only technology to measure finger finger flexion and extension forces with an accuracy of 1g with high temporal resolution (~10 ms). Forces can be measured in dynamic and static conditions, in flexion and in extension.
Dextrain develops a collaborative data platform with assessments, feed-back and algorithm to optimize training protocols and rehabilitation procedures. Training protocols are designed to match the patient’s needs and provide rich performance feedback and results promoting motivation and training intensity.
Dextrain is building the first data library for predictive machine learning to improve dexterity assessment and early detection of psychiatric and neurodegenerative diseases.